SG11201505818WA - Treatment of multiple sclerosis with laquinimod - Google Patents

Treatment of multiple sclerosis with laquinimod

Info

Publication number
SG11201505818WA
SG11201505818WA SG11201505818WA SG11201505818WA SG11201505818WA SG 11201505818W A SG11201505818W A SG 11201505818WA SG 11201505818W A SG11201505818W A SG 11201505818WA SG 11201505818W A SG11201505818W A SG 11201505818WA SG 11201505818W A SG11201505818W A SG 11201505818WA
Authority
SG
Singapore
Prior art keywords
laquinimod
treatment
multiple sclerosis
sclerosis
Prior art date
Application number
SG11201505818WA
Other languages
English (en)
Inventor
Nora Tarcic
Dan Bar-Zohar
Liat Hayardeny
Sherki Yossi Gilgun
Tali Gorfine
Volker Knappertz
Ella Sorani
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51351655&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201505818W(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of SG11201505818WA publication Critical patent/SG11201505818WA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
SG11201505818WA 2013-02-15 2014-02-13 Treatment of multiple sclerosis with laquinimod SG11201505818WA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361765394P 2013-02-15 2013-02-15
US201361911106P 2013-12-03 2013-12-03
PCT/US2014/016278 WO2014127139A1 (en) 2013-02-15 2014-02-13 Treatment of multiple sclerosis with laquinimod

Publications (1)

Publication Number Publication Date
SG11201505818WA true SG11201505818WA (en) 2015-08-28

Family

ID=51351655

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201505818WA SG11201505818WA (en) 2013-02-15 2014-02-13 Treatment of multiple sclerosis with laquinimod

Country Status (18)

Country Link
US (2) US20140235670A1 (ja)
EP (1) EP2956137A4 (ja)
JP (1) JP2016510343A (ja)
KR (1) KR20150119227A (ja)
CN (1) CN105163737A (ja)
AU (1) AU2014216199A1 (ja)
BR (1) BR112015019564A2 (ja)
CA (1) CA2900503A1 (ja)
CL (1) CL2015002181A1 (ja)
EA (1) EA201591507A1 (ja)
HK (2) HK1218251A1 (ja)
IL (1) IL240014A0 (ja)
MX (1) MX2015010296A (ja)
PE (1) PE20151526A1 (ja)
SG (1) SG11201505818WA (ja)
TW (1) TW201442709A (ja)
UY (1) UY35328A (ja)
WO (1) WO2014127139A1 (ja)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140138694A (ko) 2012-02-03 2014-12-04 테바 파마슈티컬 인더스트리즈 리미티드 최선의 항-TNFα 요법에 실패한 크론병 환자를 치료하기 위한 라퀴니모드의 용도
TW201347762A (zh) * 2012-05-02 2013-12-01 Teva Pharma 高劑量拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）於治療多發性硬化症之用途
AU2015253330A1 (en) 2014-04-29 2016-12-01 Teva Pharmaceutical Industries Ltd. Laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS) patients with a high disability status
WO2016059571A1 (en) * 2014-10-16 2016-04-21 Novartis Ag Combinations comprising siponimod and laquinimod for the treatment of multiple sclerosis
US10091217B2 (en) 2016-06-21 2018-10-02 Logrhythm, Inc. Risk based priority processing of data
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
US11167003B2 (en) * 2017-03-26 2021-11-09 Mapi Pharma Ltd. Methods for suppressing or alleviating primary or secondary progressive multiple sclerosis (PPMS or SPMS) using sustained release glatiramer depot systems
US20230296628A1 (en) * 2020-07-09 2023-09-21 Oklahoma Medical Research Foundation Biomarkers for Identifying Relapses in Multiple Sclerosis

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077851A (en) * 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
SE9801474D0 (sv) * 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
KR101495327B1 (ko) * 2006-06-12 2015-02-24 테바 파마슈티컬 인더스트리즈 리미티드 안정한 라퀴니모드 제제
AU2008275148A1 (en) * 2007-07-11 2009-01-15 Medicinova, Inc. Treatment of progressive neurodegenerative disease with ibudilast
AR073295A1 (es) * 2008-09-16 2010-10-28 Genentech Inc Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion.
US20110268699A1 (en) * 2008-12-11 2011-11-03 Biovista, Inc. Methods for treating multiple sclerosis using tetracyclic pyrazinoindoles
AU2010260455A1 (en) * 2009-06-19 2012-02-02 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis with laquinimod
BR112013014061A2 (pt) * 2010-12-07 2016-09-13 Teva Pharma uso de laquinimod para redução da fadiga, melhorando o estado fundicional e melhorando a qualidade de vida nos pacientes com esclerose múltipla
MX2014001048A (es) * 2011-07-28 2014-07-09 Teva Pharma Tratamiento de esclerosis multiple con combinacion de laquinimo de interferon-beta.
TW201347762A (zh) * 2012-05-02 2013-12-01 Teva Pharma 高劑量拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）於治療多發性硬化症之用途
JP2015533163A (ja) * 2012-10-12 2015-11-19 テバ ファーマシューティカル インダストリーズ リミティド 多発性硬化症における視床損傷を低減するためのラキニモド
AU2015253330A1 (en) * 2014-04-29 2016-12-01 Teva Pharmaceutical Industries Ltd. Laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS) patients with a high disability status

Also Published As

Publication number Publication date
BR112015019564A2 (pt) 2017-07-18
MX2015010296A (es) 2016-05-05
IL240014A0 (en) 2015-09-24
JP2016510343A (ja) 2016-04-07
CA2900503A1 (en) 2014-08-21
PE20151526A1 (es) 2015-11-20
AU2014216199A1 (en) 2015-09-03
EA201591507A1 (ru) 2015-12-30
UY35328A (es) 2014-09-30
KR20150119227A (ko) 2015-10-23
TW201442709A (zh) 2014-11-16
US20180064702A1 (en) 2018-03-08
CN105163737A (zh) 2015-12-16
HK1218254A1 (zh) 2017-02-10
EP2956137A4 (en) 2016-08-03
US20140235670A1 (en) 2014-08-21
WO2014127139A1 (en) 2014-08-21
HK1218251A1 (zh) 2017-02-10
EP2956137A1 (en) 2015-12-23
CL2015002181A1 (es) 2016-06-03

Similar Documents

Publication Publication Date Title
HRP20181296T1 (hr) Novi spojevi za suzbijanje člankonožaca
IL252547A0 (en) Treatment of multiple sclerosis using laquinimod
IL287516A (en) Medicinal uses of empagliflozin
HRP20190101T1 (hr) Terapeutske uporabe empagliflozina
HK1213818A1 (zh) 依帕列淨的治療用途
SI2981271T1 (sl) Terapevtske uporabe empagliflozina
HK1218254A1 (zh) 用拉喹莫德治療多發性硬化症
IL241096B (en) Treatment methods
HK1223855A1 (zh) 拉喹莫德和氟吡汀組合物用於治療多發性硬化症
HK1225971A1 (zh) 使用拉喹莫德治療青光眼
IL244620A0 (en) A drug combination including laquinimod for the treatment of multiple sclerosis
ZA201601626B (en) Treatment of gases
HK1227691A1 (zh) 利用拉喹莫德和特立氟胺的組合來治療多發性硬化症
GB2525530B (en) Treatment of hard surfaces
GB201322778D0 (en) Method of treatment
GB201314882D0 (en) Method of treatment